While ENZ treatment was found not to be efficacious in this context [1], it is important to determine the effects of PKC-ß inhibitors, due to the fact that activation of PKC is known to contribute to tumor cell survival, tumor cell proliferation, and decreased patient survival; therefore, this pathway will continue to be an avenue of research for cancer treatment. This evidence concerns the gene PRRT2 and neoplasm.